Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed May 14, 2026 · 10-Q · 44 days after period end · 0001493152-26-023210
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$6.36M | -$54.07M | -$526.70K | -$809.81K |
| EPS Diluted | -$0.28 | -$12.50 | -$545.79 | -$0.42 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end
